山盛(森田) 智子

Tomoko Yamamori

研究分野 (1件)：腫瘍生物学

競争的資金等の研究課題 (4件)：

2021 - 2025 染色体不安定性を有する細胞の細胞死回避メカニズムの解明
2022 - 2024 SA-T細胞を抑制する化合物の探索とその加齢性疾患改善への応用
2019 - 2021 遺伝的多様性を有する癌細胞間の環境適応勝者の決定機構の解明
2016 - 2018 細胞競合を標的とした新規がん治療薬・診断マーカーの開発

論文 (14件)：

Ryo Kamata, Hitoshi Saito, Yumi Hakozaki, Yukie Kashima, Gaku Yamamoto, Tomoko Yamamori Morita, Pinyi Lu, Akihiro Ohashi. Abstract 411: PI3K-AKT-mTOR signaling pathways play important roles in chromosomal instability-induced innate immune response in cancer cells. Cancer Research. 2024. 84. 6_Supplement. 411-411
Tomoko Yamamori Morita, Jie Yu, Yukie Kashima, Ryo Kamata, Gaku Yamamoto, Tatsunori Minamide, Chiaki Mashima, Miyuki Yoshiya, Yuta Sakae, Toyohiro Yamauchi, et al. CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade. Nature Communications. 2023. 14. 1
R. Kamata, Y. Hakozaki, Y. Kashima, T.Y. Morita, P. Lu, A. Ohashi. CENP-E inhibitor potently activates cGAS-STING pathway through misaligned chromosome-mediated micronucleation after mitotic slippage. European Journal of Cancer. 2022. 174. S47-S48
Yumi Fujimoto, Tomoko Yamamori Morita, Akihiro Ohashi, Hiroshi Haeno, Yumi Hakozaki, Masanori Fujii, Yukie Kashima, Susumu S Kobayashi, Toru Mukohara. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells. Scientific reports. 2020. 10. 1. 21762-21762
Takeshi Maruyama, Ayana Sasaki, Sayuri Iijima, Shiyu Ayukawa, Nobuhito Goda, Keisuke Tazuru, Norikazu Hashimoto, Takashi Hayashi, Kei Kozawa, Nanami Sato, et al. ZAK inhibitor PLX4720 promotes extrusion of transformed cells via cell competition. iScience. 2020. 101327-101327

MISC (1件)：

Hiroki Yamashita, Jason Guoqiang Zhang, Chiaki Mashima, Ryo Kamata, Tomoko Yamamori, Izuma Nakayama, Akihito Kawazoe, Kohei Shitara, Tomonori Yano, Qunli Xu, et al. Abstract 5075: Transcriptomic landscape of tumor microenvironment in gastric cancer in treatment with different types of cancer drugs. Cancer Research. 2024. 84. 6_Supplement. 5075-5075

講演・口頭発表等 (19件)：

Abstract 5265: Targeting mtDNA dynamics enhances immunogenicity and sensitizes <i>KRAS</i> mutant cancers to PD-1 blockade
(Cancer Research 2024)
Abstract 411: PI3K-AKT-mTOR signaling pathways play important roles in chromosomal instability-induced innate immune response in cancer cells
(Cancer Research 2024)
Abstract 5075: Transcriptomic landscape of tumor microenvironment in gastric cancer in treatment with different types of cancer drugs
(Cancer Research 2024)
BRCA2非翻訳領域上に存在する新規生殖細胞系列突然変異のメカニズム解析
(第46回日本分子生物学会年会 2023)
新規クラスター化合物Ag5の細胞死誘導メカニズムの解明
(第46回日本分子生物学会年会 2023)

学位 (1件)：

博士 (理学) (同志社大学)

所属学会 (3件)：

日本分子生物学会 , American Association for Cancer Research , 日本癌学会

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

前のページに戻る